Cargando…

The Value of Hope: Patients’ and Physicians’ Preferences for Survival in Advanced Non-Small Cell Lung Cancer

PURPOSE: Immuno-oncology treatments offer patients with advanced non-small cell lung cancer (NSCLC) treatment options with greater probability of durable survival and a different toxicity profile compared with traditional chemotherapy. The objective of this study was to explore the importance of inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauber, Brett, Penrod, John R, Gebben, David, Musallam, Lina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608144/ https://www.ncbi.nlm.nih.gov/pubmed/33154633 http://dx.doi.org/10.2147/PPA.S248295

Ejemplares similares

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis
por: Carroll, Robert, et al.
Publicado: (2022)

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Qian, Yi, et al.
Publicado: (2018)

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
por: González, Juan Marcos, et al.
Publicado: (2017)

Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer: time for hope?
por: De Ruysscher, Dirk K., et al.
Publicado: (2018)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials
por: Katz, Eva G, et al.
Publicado: (2016)

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018
por: Wolf, Andrea, et al.
Publicado: (2023)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

Hemodialysis patients’ preferences for the management of anemia
por: Hauber, Brett, et al.
Publicado: (2017)

Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
por: Mamdani, Hirva, et al.
Publicado: (2020)

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
por: Hu, Shanlian, et al.
Publicado: (2023)

The Therapeutic Value of Hope
Publicado: (1909)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
por: Campbell, David, et al.
Publicado: (2018)

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Patient Preferences Regarding Surgical Treatment Methods for Symptomatic Uterine Fibroids
por: Babalola, Olufemi, et al.
Publicado: (2023)

Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma
por: Bulbul, Yilmaz, et al.
Publicado: (2010)

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative
por: Soares, Marta, et al.
Publicado: (2020)

Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
por: Sun, Hui, et al.
Publicado: (2020)

Hemisection-hope for last survival
por: Hasija, Mukesh, et al.
Publicado: (2013)

A revealed preference analysis to develop composite scores approximating lung allocation policy in the U.S
por: Stewart, Darren E., et al.
Publicado: (2021)

Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen
por: Zhao, Jun, et al.
Publicado: (2012)

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer
por: Zhou, Shaozhang, et al.
Publicado: (2020)

Hope against hope: exploring the hopes and challenges of rural female caregivers of persons with advanced cancer
por: Williams, Allison, et al.
Publicado: (2013)

Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)
por: Hauber, A Brett, et al.
Publicado: (2011)

Prognostic Value of Survival of MicroRNAs Signatures in Non-small Cell Lung Cancer
por: Chen, Bo, et al.
Publicado: (2019)

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative
por: Snee, Michael, et al.
Publicado: (2021)

The relationship between hope, medical expenditure and survival among advanced cancer patients
por: Chay, Junxing, et al.
Publicado: (2023)

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
por: McMullen, Suzanne, et al.
Publicado: (2018)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature
por: Enstone, Ashley, et al.
Publicado: (2017)

From hesitancy to hope: One physician's experience with the Moderna trial
por: Edje, Louito C.
Publicado: (2021)

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
por: Verleger, Katharina, et al.
Publicado: (2020)

Exploring Decisional Conflict With Measures of Numeracy and Optimism in a Stated Preference Survey
por: Sutphin, Jessie, et al.
Publicado: (2021)

Baseline tumour measurements predict survival in advanced non-small cell lung cancer
por: Gerber, D E, et al.
Publicado: (2013)

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival
por: Kanaji, Nobuhiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9ea4q0dq9hkopiuj7fpk21c0kl